Edwards invests €15 Million in Affluent’s heart products #medtech #AffluentMedical #CVD #medicaldevice #EdwardsLifesciences
BioWorld News
Media and Telecommunications
Actionable intelligence on the most innovative therapeutics and medical technologies in development
About us
BioWorld’s suite of news services delivers actionable intelligence on the most innovative therapeutics and medical technologies in development. With writers and editors stationed around the globe, BioWorld reports the breaking news – and provides key perspective on hundreds of therapeutics and devices in development, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. BioWorld The flagship daily biopharmaceutical news source covers the complete lifecycle of thousands of therapies in development from around the world, the companies behind those candidates, the business development transactions that evolve the markets, and the regulatory hurdles that both challenge and guard the processes. Includes data-rich content focused on financial and strategic trends with deep analysis that helps decision makers develop dynamic strategies. BioWorld MedTech The news source of record covering the latest advances in medical technologies from around the world ranging from actual devices, such as orthopedic implants, to digital health tools. BioWorld Science News and analysis on discovery and preclinical research to support crucial drug R&D decisions at the earliest stages. BioWorld Asia The weekly monitor of biopharmaceutical developments in the Asia-Pacific region
- Website
-
https://www.bioworld.com/
External link for BioWorld News
- Industry
- Media and Telecommunications
- Company size
- 11-50 employees
- Type
- Public Company
- Founded
- 1990
Updates
-
No PD-L1? No problem for Immutep’s eftilagimod in HNSCC trial Immutep Limited #cancer BioWorld News
No PD-L1? No problem for Immutep’s eftilagimod in HNSCC trial
bioworld.com
-
ISSCR 2024: Expanding niche definition gives insights into stem cells BioWorld News
ISSCR 2024: Expanding niche definition gives insights into stem cells
bioworld.com
-
First-in-class ADC Foreseen in $1B-plus Ipsen deal Ipsen Foreseen Biotechnology #adcs #antibodydrugconjugates BioWorld News
First-in-class ADC Foreseen in $1B-plus Ipsen deal
bioworld.com
-
Physicians slam US Medicare doc fee schedule for rate cuts #medtech @CMSgov @ASTRO_org
Physicians slam US Medicare doc fee schedule for rate cuts
bioworld.com
-
A gene therapy could restore hearing in adults BioWorld News
A gene therapy could restore hearing in adults
bioworld.com
-
Illumina boldly acquires Fluent Bio weeks after Grail divestiture #medtech #PIPseq #singlecell #Illumina #FluentBiosciences
Illumina boldly acquires Fluent Bio weeks after Grail divestiture
bioworld.com
-
With Eiger’s avexitide, Amylyx ‘unique’ new player in GLP-1 Amylyx Pharmaceuticals BioWorld News
With Eiger’s avexitide, Amylyx ‘unique’ new player in GLP-1
bioworld.com
-
Myricx raises £90M in Europe’s largest series A for NMT inhibitors BioWorld News
Myricx raises £90M in Europe’s largest series A for NMT inhibitors
bioworld.com
-
Pulse Bio’s cardiac PFA system named FDA breakthrough device #medtech #PulseBiosciences #PFA #Cardiacablation
Pulse Bio’s cardiac PFA system named FDA breakthrough device
bioworld.com